Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC.FENC · Entity 5601 | Chief Commercial Officer | October 12, 2026 | October 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FENNEC PHARMACEUTICALS INC.
Report date October 12, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 24,013 |
Reported balance
After 2026-10-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-10-12 · Grant · Acquired 2,326 · Balance 24,013 F1: The Issuer's common shares were acquired pursuant to the Fennec Pharmaceuticals Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of April 9, 2026 through October 12, 2026. F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on the Nasdaq Capital Market on April 9, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The Issuer's common shares were acquired pursuant to the Fennec Pharmaceuticals Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of April 9, 2026 through October 12, 2026.
F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on the Nasdaq Capital Market on April 9, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 12, 2026 Filed Oct 13, 2026 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon Shares | 2,326 | $5.53 | $12,862.78 |
DisclosureSEC source: 0002043317-26-000016 · form4-10132026_041005.xml · nonDerivative · entry 1 Evans Terry L · CIK 0002043317 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,013 F1 · security: The Issuer's common shares were acquired pursuant to the Fennec Pharmaceuticals Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of April 9, 2026 through October 12, 2026. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on the Nasdaq Capital Market on April 9, 2026. Read SEC document |
| September 30, 2026 Filed Oct 2, 2026 00:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon Shares | 168 | $0.00 | $0.00 |
DisclosureSEC source: 0002043317-26-000014 · form4-10012026_041007.xml · nonDerivative · entry 1 Evans Terry L · CIK 0002043317 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,687 F1 · security: Represents shares released from restriction from shares awarded 3/28/2025. Read SEC document |
| August 31, 2026 Filed Sep 1, 2026 00:13 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon Shares | 168 | $0.00 | $0.00 |
DisclosureSEC source: 0002043317-26-000012 · form4-09012026_120948.xml · nonDerivative · entry 1 Evans Terry L · CIK 0002043317 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,519 F1 · security: Represents shares released from restriction from shares awarded 3/28/2025. Read SEC document |
| July 31, 2026 Filed Aug 3, 2026 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon Shares | 168 | $0.00 | $0.00 |
DisclosureSEC source: 0002043317-26-000010 · form4-08032026_040809.xml · nonDerivative · entry 1 Evans Terry L · CIK 0002043317 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,351 F1 · security: Represents shares released from restriction from shares awarded 3/28/2025. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:38 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon Shares | 168 | $0.00 | $0.00 |
DisclosureSEC source: 0002043317-26-000008 · form4-07012026_080754.xml · nonDerivative · entry 1 Evans Terry L · CIK 0002043317 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,183 F1 · security: Represents shares released from restriction from shares awarded 3/28/2025. Read SEC document |
| May 31, 2026 Filed Jun 1, 2026 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon Shares | 168 | $0.00 | $0.00 |
DisclosureSEC source: 0002043317-26-000006 · form4-06012026_040607.xml · nonDerivative · entry 1 Evans Terry L · CIK 0002043317 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,015 F1 · security: Represents shares released from restriction from shares awarded 3/28/2025. Read SEC document |
| April 30, 2026 Filed May 1, 2026 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares | 168 | $0.00 | $0.00 |
DisclosureSEC source: 0002043317-26-000004 · form4-05012026_040507.xml · nonDerivative · entry 1 Evans Terry L · CIK 0002043317 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,847 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents shares released from restriction from shares awarded 3/28/2025. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Options · Derivative | 120,000 | $5.77 Strike: $5.77 | $692,400.00 |
DisclosureSEC source: 0002043317-26-000002 · form4-04022026_040409.xml · derivative · entry 4 Evans Terry L · CIK 0002043317 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 270,000 Underlying: Common Shares · 120,000 shares Expires 2036-03-31 F3 · security: On March 31, 2026, granted incentive stock options to purchase 120,000 shares of the issuers common shares pursuant to the Issuer's 2020 Equity Incentive Plan. F4 · derivative.exercise_date: One-third of the shares subject to this option may be exercised as of March 31, 2027 ("Vesting Commencement Date"). One twenty-fourth of the shares subject to this option shall vest and may be exercised as of the last day of each month following the Vesting Commencement Date. As of March 31, 2029, 100% of the total number of shares subject to this option shall be vested. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon shares | 171 | $0.00 | $0.00 |
DisclosureSEC source: 0002043317-26-000002 · form4-04022026_040409.xml · nonDerivative · entry 2 Evans Terry L · CIK 0002043317 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,627 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Represents shares released from restriction from shares awarded 3/28/2025. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares | 18,456 | $0.00 | $0.00 |
DisclosureSEC source: 0002043317-26-000002 · form4-04022026_040409.xml · nonDerivative · entry 1 Evans Terry L · CIK 0002043317 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,456 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents settlement of PSUs that vested on March 31, 2026. Read SEC document |
| March 28, 2026 Filed Apr 2, 2026 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon shares | 2,052 | $0.00 | $0.00 |
DisclosureSEC source: 0002043317-26-000002 · form4-04022026_040409.xml · nonDerivative · entry 3 Evans Terry L · CIK 0002043317 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,679 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Represents shares released from restriction from shares awarded 3/28/2025. Read SEC document |
| March 28, 2025 Filed Apr 3, 2025 22:11 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantRestricted Share Unit · Derivative | 10,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-010055 · form4-04032025_100449.xml · derivative · entry 1 Evans Terry L · CIK 0002043317 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Shares · 10,000 shares Expires 2035-03-28 F1 · security: On March 28, 2025,Terry Evans was awarded restricted share units to acquire 10,000 shares of the issuer's common shares pursuant to the issuer's 2020 Equity Incentive Plan. F2 · derivative.exercise_date: One-third of the shares subject to this award shall be released from restriction as of March 28, 2026 (the "Vesting Commencement Date"). One twenty-fourth of the shares subject to this award may be released from restriction as of the last day of each month following the Vesting Commencement Date. As of February 29, 2028 and thereafter, 100% of the total number of shares subject to this award shall be released from restriction. Read SEC document |
| March 28, 2025 Filed Apr 3, 2025 23:14 UTC Amendment | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantRestricted Share Unit · Derivative | 10,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-010067 · form4a-04032025_110435.xml · derivative · entry 1 Evans Terry L · CIK 0002043317 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Shares · 10,000 shares Expires 2035-03-28 F1 · security: On March 28, 2025,Terry Evans was awarded restricted share units to acquire 10,000 shares of the issuer's common shares pursuant to the issuer's 2020 Equity Incentive Plan. F2 · derivative.exercise_date: One-third of the shares subject to this award shall be released from restriction as of March 28, 2026 (the "Vesting Commencement Date"). One twenty-fourth of the shares subject to this award may be released from restriction as of the last day of each month following the Vesting Commencement Date. As of February 29, 2028 and thereafter, 100% of the total number of shares subject to this award shall be released from restriction. Read SEC document |
| November 13, 2024 Filed Nov 13, 2024 22:14 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Options · Derivative | 150,000 | $4.23 Strike: $4.23 | $634,500.00 |
DisclosureSEC source: 0001415889-24-026723 · form4-11132024_101115.xml · derivative · entry 1 Evans Terry L · CIK 0002043317 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Shares · 150,000 shares Expires 2034-11-13 F1 · security: On November 13, 2024,Terry Evans was granted incentive stock options to purchase 150,000 shares of the issuers common shares pursuant to the Issuer's 2020 Equity Incentive Plan. F2 · derivative.exercise_date: One-third of the shares subject to this option may be exercised as of November 13, 2025 ("Vesting Commencement Date"). One twenty-fourth of the shares subject to this option shall vest and may be exercised as of the last day of each month following the Vesting Commencement Date until all shares have vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.